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Abstract
Introduction: Guillain-Barré syndrome (GBS) is an autoimmune disease that results in acute paralysis through
inflammatory attack on peripheral nerves, and currently has limited, non-specific treatment options. The pathogenesis
of the acute motor axonal neuropathy (AMAN) variant is mediated by complement-fixing anti-ganglioside antibodies
that directly bind and injure the axon at sites of vulnerability such as nodes of Ranvier and nerve terminals.
Consequently, the complement cascade is an attractive target to reduce disease severity. Recently, C5 complement
component inhibitors that block the formation of the membrane attack complex and subsequent downstream injury
have been shown to be efficacious in an in vivo anti-GQ1b antibody-mediated mouse model of the GBS variant Miller
Fisher syndrome (MFS). However, since gangliosides are widely expressed in neurons and glial cells, injury in this model
was not targeted exclusively to the axon and there are currently no pure mouse models for AMAN. Additionally, C5
inhibition does not prevent the production of early complement fragments such as C3a and C3b that can be
deleterious via their known role in immune cell and macrophage recruitment to sites of neuronal damage.
Results and Conclusions: In this study, we first developed a new in vivo transgenic mouse model of AMAN
using mice that express complex gangliosides exclusively in neurons, thereby enabling specific targeting of axons
with anti-ganglioside antibodies. Secondly, we have evaluated the efficacy of a novel anti-C1q antibody (M1) that
blocks initiation of the classical complement cascade, in both the newly developed anti-GM1 antibody-mediated
AMAN model and our established MFS model in vivo. Anti-C1q monoclonal antibody treatment attenuated
complement cascade activation and deposition, reduced immune cell recruitment and axonal injury, in both mouse
models of GBS, along with improvement in respiratory function. These results demonstrate that neutralising C1q
function attenuates injury with a consequent neuroprotective effect in acute GBS models and promises to be a useful
new target for human therapy.
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Introduction
The autoimmune inflammatory neuropathy Guillain-
Barré syndrome (GBS) causes rapid onset paralysis,
with patients often requiring artificial ventilation, and in
severe cases leads to permanent disability through axon
loss. Treatment with IVIg and plasmapheresis are beneficial
[21], but are non-specific and have unclear mechanisms of
action. To develop and test a new generation of therapeu-
tics it is crucial to create a relevant animal model that can
be used to both understand the pathophysiology and valid-
ate the suitability of potential intervention. GBS is in part
mediated by anti-ganglioside antibodies induced by preced-
ing bacterial infections including Campylobacter jejuni
enteritis [40]. Anti-ganglioside antibodies then target nerve
surface gangliosides, glycolipids found extensively in ner-
vous tissue membranes [20]. In particular, the axonal vari-
ant of GBS (acute motor axonal neuropathy, AMAN) is
strongly associated with circulating anti-GM1 and GD1a
ganglioside antibodies [17, 25], which can target and bind
to axonal and nodal membranes, whilst the Miller Fisher
syndrome (MFS) variant is associated with circulating anti-
GQ1b ganglioside antibodies with distinct tissue specificity
for cranial nerves [3]. Clinical and experimental evidence
suggests the pathogenic mechanisms in GBS include com-
plement fixation by these autoantibodies, leading to clas-
sical pathway activation. Complement components have
been identified along patient nerve Schwann cell abaxonal
membrane in demyelinating GBS [10, 30], and C3d and the
terminal membrane attack complex (MAC) pore have been
located on the axolemma along the internode and at the
node of Ranvier in AMAN [8, 9]. Animal modelling indi-
cates that complement deposition at the node of Ranvier
with insertion of the MAC pore will allow the uncontrolled
influx of calcium ions, which in turn disrupts ionic homeo-
stasis and initiates calpain cleavage of structural and chan-
nel proteins including neurofilament and voltage-gated Na+
channels [14, 22, 36]. Terminal complement MAC pore
formation is linked to acute injury and dysfunction, but the
complement cascade also consists of pro-inflammatory
components that can recruit immune cells, which them-
selves may contribute to pathogenesis. Indeed, macro-
phages have been found extensively in autopsy tissue [8, 9]
and while they participate in clearance of debris to pro-
mote recovery, they could also have a role in expanding
nervous tissue damage through complement directed, cell-
mediated attack. Therefore, the complement cascade has
great potential as a target for therapeutic intervention [39].
Inhibition of terminal complement activation products has
been tested recently in animal models [12, 13, 15, 22, 27].
In GBS mouse models we have reported that C5 comple-
ment component inhibition prevented MAC pore forma-
tion and consequent axonal degeneration [12, 13, 15, 22].
Inhibition of C5, however, does not eliminate the produc-
tion of early complement activation products that induce
immune cell recruitment to the site of injury and which
could cause further damage or delayed recovery. C1q is
the first complement cascade molecule in the classical
pathway, and binds pathogenic autoantibodies to initiate
the cascade. Therefore its inhibition will prevent down-
stream activation of only the classical pathway, leaving the
alternative and mannose-binding lectin pathways intact to
counter bacterial infection [28]. In this report, we specific-
ally examine the role of the classical complement cascade
by using a mouse monoclonal antibody that inhibits the
function of C1q. A similar antibody was shown to effect-
ively reduce inflammatory demyelinating lesions in an in
vivo mouse model of the complement-dependent disease
neuromyelitis optica [28].
For the current study we have applied a mouse model
of the AMAN form of GBS using a newly developed
transgenic mouse that solely expresses complex ganglio-
sides neuronally [41], thus allowing us to specifically tar-
get and injure axons with an anti-GM1 ganglioside
antibody. An additional benefit to this mouse strain is that
circulating anti-ganglioside antibody will not be seques-
tered by other extra-neural plasma membranes which
would reduce the bioavailability of the antibodies for bind-
ing axonal membranes (Cunningham et al., in press). We
found that the function-blocking antibody against C1q in-
hibits pathogenesis in both models of GBS – the MFS
model used in our previous study, as well as the new
AMAN model described in this report. Our results dem-
onstrate that targeting C1q, the initiating molecule of the
classical complement cascade, led to axonal protection,
improved function and reduced immune cell recruitment,
providing proof of concept for anti-C1q targeted therapies
in GBS.
Materials and methods
Mice
For anti-GQ1b/GD3 antibody mediated injury experi-
ments, Balb/c wild type mice, obtained from Harlan (UK)
were used as previously reported. For the anti-GM1 IgG
antibody mediated AMAN model GalNAcT−/−-Tg(neuro-
nal) transgenic on a C57Bl/6 background were used. For
anti-ganglioside antibody binding assessment Balb/c wild
type mice, GalNAcT−/−-Tg(neuronal) transgenic and wild-
type mice both on a C57Bl/6 background were used. All
mice were 4 weeks old (12–15 g). Mice had unlimited
access to food and water, and housed with a light/dark
cycle of 12 h/12 h and constant temperature at 22 °C. Gal-
NAcT−/−-Tg(neuronal) mice express the full-length cDNA
encoding GalNAcT under the control of the Thy1.2 pro-
moter (restricted to mature neurons) similarly to previ-
ously reported mice under NFL promoter activity [41].
GalNAcT cDNA (1655 bp) (provided by Koichi Furukawa)
was cloned into the pTSC21K vector (provided by Matthias
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Eckhardt/Herman van der Putten) for generating Thy1.2–
GalNAcT transgenic mice. Transgenic lines and germ-line
transmitters were identified by PCR and backcrossed seven
generations on a C57BL/6 background. Thy1.2–GalNAcT
mice were then interbred with GalNAcT−/− mice [37] to
create 2 lines of GalNAcT−/−-Tg(neuronal) mice. Evidence
for restoration of GalNAcT enzyme activity in both lines
was confirmed by glycosyltransferase activity assays as
described previously ([34, 35]; Fig 1a) and evidenced by
complex ganglioside synthesis in neural tissues demon-
strated by thin layer chromatography overlay (Fig 1c)
and immunohistology (Fig 1d) as described previously
[41]. For illustrative images, transgenic mice that add-
itionally express cyan fluorescent protein (CFP) in their
axons [5] were used. Mice of either sex were killed by
CO2 inhalation. All experiments using mice were per-
formed in accordance with a licence approved and
granted by the United Kingdom Home Office and con-
formed to University of Glasgow institutional guide-
lines. Experiments complied with relevant guidelines
outlined in the revised Animals (Scientific Procedures)
Act 1986.
Monoclonal antibodies and normal human serum
The IgM anti-GQ1b/GD3 ganglioside monoclonal anti-
body (mAb), CGM3, was derived from mice inoculated
with a GT1a-bearing C. jejuni lipooligosaccharide (GQ1b,
GD3 and GT1a possess a structural mimic in their ter-
minal trisaccharide to which CGM3 binds) [6]. CGM3
was selected for the MFS model as it induces identical
complement-dependent pathogenic effects as human MFS
sera in vitro [2, 18, 29]. The IgG3 anti-GM1 ganglioside
mAb, DG2, was derived from GalNAcT−/− mice inocu-
lated with the GM1 ganglioside mimicking HS19 lipooli-
gosaccharide [1]. CGM3 and DG2 concentration was
measured using quantitative ELISA (Bethyl Laboratories,
Texas, USA). The mouse anti-C1q antibody, M1, and a
non-specific isotype control IgG1 mAb were provided by
Annexon Biosciences (California, USA). Monoclonal anti-
body M1 binds and neutralises C1q and thereby prevents
binding to anti-ganglioside antibody Fc domain and the
activation of the classical complement cascade. This anti-
body is also capable of binding mouse C1q, but since
mouse complement is highly regulated by endogenous in-
hibitors its activation is not involved in injury in our
models, as previously shown [39]. Normal human serum
(NHS) was collected from a single donor, rapidly frozen
and stored in multiple aliquots at −70 °C to preserve com-
plement activity.
In vivo model
Balb/c mice were injected intraperitoneally (i.p.) with
1.5 mg anti-GQ1b/GD3 ganglioside IgM mAb for the
MFS model and GalNAcT−/−-Tg(neuronal) mice were
injected i.p. with 1.5 mg anti-GM1 ganglioside IgG mAb
for the AMAN model. After 16 h, mice were injected
intravenously (i.v.) into the tail vein with 50 mg/kg anti-
C1q neutralising antibody or isotype control mAb to test
the effect of anti-C1q inhibition. Several doses were
trialled and results indicated that 50 mg/kg was the max-
imally effective dose, consistent with previous studies [28].
After a further 30 min interval, 0.5 ml 100 % NHS was de-
livered i.p. The separation of NHS and anti-C1q or control
antibody delivery by time and region was performed to
avoid immediate inhibition of C1q within the peritoneal
cavity. Mice were observed for a further 4–6 h and ana-
lysed for whole-body plethysmography, rotarod and grip
strength performance (see below). At 6 h, mice were
asphyxiated with a rising concentration of CO2, and blood,
diaphragm and soleus muscles collected for serum and
immunohistochemical analysis.
Plethysmography and behavioural analysis
After training, baseline measurements were collected for
all functional and behavioural analysis and were not sig-
nificantly different between groups for any parameter
(see Results). Due to its proximity to the antibody and
NHS delivery site, the diaphragm and associated phrenic
nerve is the major target structure in this in vivo model;
therefore whole-body plethysmography (EMMS, Hants,
UK) was employed as a non-invasive method for measur-
ing respiratory output and related functional deficits.
Interpretation of plethysmography data is complex; even
minimal intervention studies (e.g. venepuncture) can cause
respiratory measurement fluctuation [32]. Nevertheless
these recordings are sensitive and provide useful quantifi-
cation of respiratory failure that could not be achieved by
observation, as previously reported [15]. Mice were accli-
matised to the equipment and baseline levels recorded
before anti-ganglioside antibody injection. Mice were
allowed to settle for 30 min, and 5.5 h after NHS delivery,
flow-derived parameters of breath frequency and tidal vol-
ume were collected from 25 accepted breaths and aver-
aged over this 30 min period. Mice were trained on the
accelerating rotarod (30 – 60 rpm for 5 min) prior to
treatment. Baseline measurements of the length of time to
stay on the rotarod were recorded; subsequently measure-
ments taken 4 h after NHS treatment were calculated as a
percentage of this value and compared between groups.
Grip strength was performed as described previously [19].
Both fore-limb and all four limb measurements were col-
lected to calculate the hind-limb grip strength (fore-limb
subtracted from all four limb), and similarly compared to
baseline measurements. Statistical analysis was performed
using GraphPad Prism 6 software (GraphPad Software
Inc., La Jolla, CA), where significance p < 0.05. Student t-
tests were applied to compare conditions.
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Fig. 1 (See legend on next page.)
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Immunoassays
ELISA
To test for anti-ganglioside antibody reactivity in the mouse
sera, ganglioside ELISAs were performed. Immulon-2HB
96 well plates (Thermo Fisher Scientific, MA, USA), were
coated with 100 μl at 2 μg/ml of GM1 (Sigma, Aldrich) or
GQ1b (Matreya) diluted in methanol, or methanol only for
control wells. The average OD reading from control wells
was subtracted from all other wells to correct for back-
ground. Plates were blocked with 2 % bovine serum albu-
min (BSA)/PBS solution for 1 h at 4 °C. Block was
discarded and mouse serum (1/50 in 0.1 % BSA solution)
added overnight at 4 °C. Anti-GM1 and anti-GQ1b mono-
clonal antibodies DG2 and CGM3, respectively, were used
as positive controls and were applied at 50 μg/ml in 0.1 %
BSA. Plates were washed 3x in PBS then secondary anti-
body (goat anti-mouse IgG or IgM-HRP, 1:3000, Sigma
Aldrich) was added in 0.1 % BSA solution for 1 h at 4 °C.
After PBS washes, OPD substrate solution (30 ml dH2O,
16 ml 0.2 M Na2HP04, 14 ml 0.IM C6HgO7, 1 OPD tab-
let and 20 μl 30 % H2O2 added immediately prior to use)
was added for 20 min at room temperature (R.T.),
followed by stop solution (4 M H2SO4). Plates were read
at 492 nm on a Tecan Sunrise™ automated microplate
reader (Tecan Group Ltd, Männedorf, Switzerland) using
Magellan™ software.
Anti-C1q antibody assay
Serum levels of anti-C1q antibody were measured by
ELISA. Black 96 well plates (Costar) were coated with 2 μg/
ml of human C1q (Complement Technology) in bicarbon-
ate buffer (pH 9.4) overnight at 4 °C. Next day, the plates
were washed with PBS (pH 7.4) (Thermo Scientific) and
then blocked with PBS buffer containing 3 % BSA. Anti-
C1q antibody standard curve was prepared in the range of
50–0.02 ng/ml in control mouse serum at 1/1,000,000 dilu-
tion in dPBS containing 0.3 % BSA and 0.1 % tween. Study
serum samples were diluted at 1/1,000,000 in the same
buffer. The blocking buffer was removed from the plate.
Standards and samples were added at 50 μl per well and in-
cubated shaking at 300 rpm at R.T. for 1 h. Then, 50 μl of
alkaline-phosphatase conjugated goat anti-mouse antibody
was added to all wells. After an additional hour of incuba-
tion at R.T., plates were washed thrice with dPBS contain-
ing 0.05 % Tween. Plates were then developed using 100 μl
of alkaline phosphatase substrate (Life Technologies). After
incubation for 20 min, plates were read using a lumin-
ometer. Standards were fit using a 4PL logistic fit and un-
knowns converted to concentration. Sample anti-C1q
antibody levels were corrected for dilution and then plotted.
Human C1q assay
Serum levels of human C1q were measured using a sand-
wich ELISA. Black 96 well plates (Costar) were coated with
1 μg/ml of JL1 antibody (Abcam) in bicarbonate buffer
(pH 9.4) overnight at 4 °C. Next day, the plates were
washed with dPBS (pH 7.4) and then blocked with dPBS
buffer containing 3 % BSA. Human C1q (Complement
Technology) standard curve was prepared in the range of
200–0.01 ng/ml in dPBS containing 0.3 % BSA and 0.1 %
tween. Study serum samples were prepared in the same
buffer at 1/10,000 to 1/30,000. The blocking buffer was re-
moved from the plate. Standards and samples were added
at 50 μl per well and incubated shaking at 300 rpm at R.T.
for 1 h. Then, 50 μl of alkaline-phosphatase conjugated
human-C1q-specific antibody was added to all wells (clone
4A4B11 hybridoma from ATCC HB-8327TM). Plates were
incubated overnight with shaking at 4 °C. Next day, plates
were washed thrice with dPBS containing 0.05 % Tween
and then developed using 100 μl of alkaline phosphatase
substrate (Life Technologies). After incubation for 20 min,
plates were read using a luminometer. Standards were fit
using a 4PL logistic fit and unknowns converted to concen-
tration. Sample C1q levels were corrected for dilution and
then plotted.
Immunostaining
Diaphragms were removed upon termination of the experi-
ment, snap frozen, and stored at −70 °C. Tissue was
mounted in OCT mounting medium and longitudinal
cryosections collected at 8–15 μm on to coated slides. Sec-
tions were stored at −20 °C until use. Immunostaining for
complement deposits and axonal integrity at the nerve
terminal was performed as previously described [15].
(See figure on previous page.)
Fig. 1 Comparison of ganglioside expression and localisation in wild type and novel GalNAcT−/−(Tg-neuronal) mice that exclusively express complex
gangliosides in neurons. a Enzyme activity assays showed a restoration of GalNAcT activity to ~50 % in 2 different GalNAcT−/−-Tg(neuronal) lines
compared to wild type (n = 3/genotype). The dashed line represents the threshold level of activity for the assay therefore GalNAcT−/− falls below this
and is essentially zero despite minimal value. b Ganglioside biosynthetic pathway. The GalNAcT enzyme is necessary for generation of complex
gangliosides (surrounded by the green box). c Brain extracts from wild type, GalNAcT−/− and 2 strains of GalNAcT−/−-Tg(neuronal) were probed with
anti-GM1 IgG antibody, DG2. This antibody bound all genotype extracts except for GalNAcT−/− which lack complex gangliosides including GM1. GM1
lipid was printed on the left and provided a positive control for anti-GM1 antibody binding. d Axonal binding can be observed in the
GalNAcT−/−-Tg(neuronal) mice treated with anti-GM1 antibody (arrows), while it bound to the terminal kranocyte (asterisk) in wild type mice
and was absent in GalNAcT−/− tissue. Anti-GQ1b/GD3 antibody bound similarly in both strains along the axons and on the perisynaptic Schwann cell
membranes (arrowheads) that are simple ganglioside GD3 positive. Scale bar = 10 μm
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Briefly, nerve terminals, were identified by Alexa Fluor 555
conjugated α-bungarotoxin (α-BTx, 1.3 μg/ml, Molecular
Probes). FITC-labelled rabbit anti-C3c (1:300, Dako, UK),
FITC conjugated anti-mouse IgG/M (1:300, Southern bio-
tech) or anti-human C5b-9 (1:50, Dako) were applied for
1 h at 4 °C. FITC conjugated goat anti-mouse IgG2a (1:300,
Southern biotech) was applied for 1 h at 4 °C to detect
C5b-9. For neurofilament staining, sections were incubated
for 1 h at 4 °C with Alexa Fluor 555 conjugated α-BTx as
above, rinsed, immersed in 100 % ethanol at −20 °C for
20 min, then incubated overnight at 4 °C with rabbit
anti-neurofilament heavy antibody (1:750, 1211, Enzo
Life sciences, UK) followed by FITC conjugated goat
anti-rabbit IgG (1:300; Southern Biotech) for 3 h at
4 °C. All detection antibodies were diluted in phos-
phate buffered saline (PBS).
For illustrative images, whole mount triangularis
sterni (TS) muscle ex vivo preparations were used, as
described previously [15]. Briefly, the muscle was re-
moved and maintained alive in oxygenated (95 % O2/
5 % CO2) Ringer’s solution 116 mM NaCl, 4.5 mM KCl,
1 mM MgCl2, 2 mM CaCl2, 1 mM NaH2PO4, 23 mM
NaHCO3, 11 mM glucose, pH 7.4). Muscle was treated
with Alexa Fluor 555 conjugated α-BTx (2 μg/ml) and
either 100 μg/ml anti-GM1 IgG3 antibody (DG2) or anti-
GQ1b IgM antibody (CGM3) for 2 h at 32 °C, transferred
to 4 °C for 30 min and a final 10 min at R.T. before rinsing
in Ringer’s. Anti-C1q antibody or control mAb was added
to 40 % NHS giving a concentration of 100 μg/ml 10 min
before application to the preparations for 1 h at R.T. Tissue
was then treated with a combinations of C3c and MAC in
Ringer’s medium for 1 h at R.T., followed by fixation with
4 % paraformaldehyde in PBS. Application of 0.1 M glycine
for 10 min was performed to quench unreactive aldehyde
groups. Antibodies and α-BTx AF-647 were reapplied in
PBS overnight at 4 °C. For staining intracellular neurofila-
ment, muscle was fixed in 4 % formaldehyde for 20 min
followed by 10 min in 0.1 M glycine and then incubated in
a permeabilizing solution containing 0.5 % Triton-X100 in
PBS for 30 min at R.T., and rabbit anti-neurofilament
(1:200) diluted in permeabilizing solution applied overnight
at R.T. Tissue was rinsed in PBS and incubated in the fol-
lowing fluorescently conjugated antibodies diluted 1:300;
anti-rabbit IgG-FITC and anti-mouse IgG-TRITC and agi-
tated for 3 h at room temperature in the dark. Tissue was
rinsed in PBS and mounted in Citifluor mounting medium
(Citifluor Products, UK). For the assessment of anti-
ganglioside antibody binding only, tissue was washed and
fixed with 4 % paraformaldehyde in PBS immediately after
anti-GM1 IgG3 (DG2) and anti-GQ1b IgM (CGM3) anti-
body incubation. Application of 0.1 M glycine for 10 min
was performed to quench unreactive aldehyde groups.
Tissue was then incubated overnight at 4 °C with anti-
mouse IgG/M-FITC (1:300) in PBS. Tissue was rinsed in
PBS and mounted in Citifluor mounting medium (Citi-
fluor Products, UK).
For immune cell staining, 15 μm diaphragm sections
were used. Sections were incubated with α-BTx (1.3 μg/
ml) for 1 h at 4 °C. To identify CD11b-positive leukocytes,
sections were incubated with 4 % PFA for 10 min at 4 °C,
washed 3x in PBS then blocked for 30 min in 3 % normal
goat serum in PBS at 4 °C. Rat anti-mouse CD11b
(MCA711G, Serotec) was applied overnight at 4 °C at a di-
lution of 1:100. For macrophage and neutrophil staining,
sections were fixed in freezing ethanol for 10 min before
the blocking step. Rat anti-mouse F4/80 (MCAP497, Sero-
tec) was applied overnight in blocking solution at a dilution
of 1:300. Neutrophil marker antibody (NIMP-R14 sc-
59338, Santa Cruz Biotechnology) was added at 1:50 over-
night in blocking solution. The following day, slides were
washed for 3 × 5 min in PBS before FITC-conjugated anti-
rat IgG secondary antibodies (Southern Biotech) were ap-
plied for 3 h at 4 °C. Vectashield mounting media with
DAPI was applied and slides were coverslipped and stored
at −20 °C before imaging.
Image capture and analysis
Digital images were captured using both a Zeiss Pascal
confocal laser scanning microscope and a Zeiss Axio
Imager Z1 with ApoTome attachment. For quantitative
analysis of IgM, C3c, MAC and neurofilament, staining
was performed in triplicate for each marker, and quanti-
fied as previously described [23]. For each marker 45 im-
ages were captured per mouse and at least 100 nerve
terminals analysed. A qualitative binary approach was
used to determine axonal integrity in the AMAN mouse
model as follows: by immunostaining, degenerating neu-
rofilament often appears abnormally fragmented, in con-
trast to well defined branching pattern seen in normal
conditions. Accordingly, though the axons may be clearly
disrupted, the immunostaining remained over the α-BTx
post-synaptic marker thereby resulting in an “intact”
axonal integrity result using the analysis software. To
overcome this anomaly, terminals were assessed by eye for
a normal/abnormal neurofilament immunostaining con-
formation and the data presented as a percentage of the
total terminals. All studies were observer blinded and sta-
tistically analysed using GraphPad Prism 6 software, as-
suming a significance level when p < 0.05. Outliers of
antibody intensity measurements were removed via
ROUT analysis (Q = 1 %). For analysis of non-parametric
immunohistological data, Mann–Whitney test was used
to compare median values per mouse. Box-and-whisker
plots were used to display the spread of all data points
from each animal. For immune cell analysis, sections were
imaged using consistent settings. Images were taken of the
NMJ as identified by α-BTx staining, using a 40x objective.
Fifteen images were taken per animal per slide. The
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number of CD11b or NIMP-R14 positive cells per field of
view (FOV) was counted and averaged per animal. All
parametric data was compared by student t-test.
Results
Anti-ganglioside antibody binding in different mouse strains
GalNAc-transferase (GalNAcT) is required for the enzym-
atic biosynthesis of complex gangliosides, and in wild type
mice the gene is widely expressed in neuronal, glial and
other tissues. In order to limit ganglioside expression to
mature neurons, we generated transgenic mice that express
GalNAcT under the Thy1.2 promoter, and crossed these
mice with mice lacking the endogenous gene through tar-
geted mutation [37]. As predicted, GalNAcT−/−-Tg(neur-
onal) mice express complex ganglioside exclusively in
neurons through expression of the GalNAcT enzyme
on the Thy1 promoter (Fig 1b and see Methods) [41].
GalNAcT enzyme activity in whole-brain homogenates
was greatly reduced in GalNAcT−/− mice when compared
to WT mice (Fig 1a). GalNAcT−/−-Tg(neuronal) lines dis-
played ~50 % activity compared to WT mice, demonstrat-
ing partial rescue of GalNAcT enzyme activity (Fig 1a). To
confirm the reintroduction and presence of GM1 in these
strains, ganglioside fractions were extracted from brains
and assessed by anti-GM1 antibody binding. GM1 was
evident in GalNAcT−/−-Tg(neuronal) and wild type sam-
ples, but not in GalNAcT−/− extracts, thereby demonstrat-
ing that GM1 had been functionally reconstituted in the
GalNAcT−/−-Tg(neuronal) mice (Fig 1c). To determine the
precise tissue localisation of the reconstituted complex gan-
gliosides, whole-mount triangularis sterni nerve-muscle
preparations from wild type and GalNAcT−/−-Tg(neuronal)
mice were incubated with anti-GM1 IgG or anti-GQ1b/
GD3 IgM antibody and the binding patterns between geno-
types were examined (Fig 1d). Anti-GM1 IgG antibody
binding is completely restricted to the axolemma at the
motor nerve terminal (delineated by endogenous axonal
CFP expression) and the nodes of Ranvier (indicated by
arrow) in GalNAcT−/−-Tg(neuronal) mice. Wild type nerve-
muscle preparations exhibited anti-GM1 antibody binding
that overlay the terminal on the membrane of parajunc-
tional fibroblasts termed kranocytes (indicated by asterisk),
as has been reported previously [7]. Anti-GM1 IgG3 anti-
body binding is absent from GalNAcT−/− mice nerve termi-
nals, a finding we have reported previously [7]. These
results indicate that anti-GM1 IgG antibody binds ex-
clusively to axons, and not to supporting cells in the
GalNAcT−/−-Tg(neuronal) mice, thereby providing evi-
dence for GalNAcT−/−-Tg(neuronal) mice and anti-GM1
IgG for the development of a pure AMAN model in mice.
Conversely, anti-GQ1b/GD3 IgM antibody binds the
axons and perisynaptic Schwann cells (indicated by arrow-
heads) of both mouse strains owing to the retained
expression of simple ganglioside GD3 at the latter site (see
Fig 1b), and GQ1b on the axon. Therefore, we elected to
use anti-GQ1b/GD3 IgM antibody mediated injury in WT
mice as the MFS model for assessment of C1q comple-
ment inhibition.
Treatment with anti-C1q neutralising antibody reduced
levels of human C1q in mouse serum
Mouse sera were collected at the end of the in vivo ex-
periments to confirm anti-ganglioside antibody and anti-
C1q antibody levels, and assess the impact on circulating
human C1q levels (Table 1). Anti-ganglioside antibody
was present at comparable levels in all mice from both
MFS and AMAN models, confirming an equal delivery
of antibody in both anti-C1q antibody and isotype control
antibody treated mice. Anti-C1q antibody levels were in
the range of 4000–6000 μg/ml in all treated mice, verify-
ing successful systemic delivery of the C1q neutralising
antibody. Human C1q levels in the sera were undetectable
in mice treated with anti-C1q antibody in both the MFS
(p < 0.01) and AMAN models (p < 0.001) when compared
to isotype control antibody treated mice. Mouse C1q
levels were also significantly reduced by anti-C1q antibody
treatment, consistent with what is known about the anti-
body’s cross-species binding (data not shown).
Treatment with C1q neutralising antibody protects
against neuropathy in a mouse model of MFS
We previously reported that balb/c wild type mice receiv-
ing an i.p. injection of anti-GQ1b/GD3 IgM antibody,
followed 16 h later by i.p. administration of normal human
serum (NHS, as a source of human complement) develop
weakness and difficulty in breathing over the subsequent
6 h [15]. This phenotype reflects intra-diaphragmatic nerve
and nerve terminal injury due to the proximity of the dia-
phragm to the site of anti-ganglioside antibody and
Table 1 Serum analysis demonstrates M1 treatment is associated with reduced circulating C1q
MFS model AMAN model
M1 (n=4) control mAb (n=3) M1 (n=5) control mAb (n=5)
AGAb serum levels (μg/ml) 0.26 ± 0.02 0.21 ± 0.04 0.42 ± 0.017 0.43 ± 0.023
M1 antibody serum levels (μg/ml) 5656 ± 518.7*** 0.0 ± 0.0 4116 ± 496.4*** 0.0 ± 0.0
C1q serum levels (μg/ml) 0.83 ± 0.5** 21.25 ± 3.6 1.175 ± 0.56** 15.08 ± 2.2
All values indicate mean ± SEM, **p<0.01, ***p<0.001 compared to control mAb per model, unpaired students t-test
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complement delivery in the peritoneal cavity. In this study,
we replicated this model and found a severe paralytic
phenotype, exactly as seen in our previous study [15]. Re-
spiratory function was assessed by whole body plethysmog-
raphy prior to, and ~5 h after NHS injection. Baseline
measurements of tidal volume (anti-C1q antibody = 0.32 ±
0.07 ml, n = 4; control mAb = 0.3 ± 0.06 ml, n = 4) were not
significantly different between the treatment groups. Mice
were treated i.v. with either 50 mg/kg anti-C1q antibody or
isotype control antibody 30 min prior to the peritoneal in-
jection of NHS. Mice treated with isotype control anti-
body showed a ~41 % reduction in baseline tidal
volume (59.3 ± 4.3 %, n = 3, p < 0.05). This was a signifi-
cant decrease in contrast to mice treated with anti-C1q
antibody (125 ± 21.9 %, n = 4) (Fig 2a), which showed no
significant differences in respiratory output from baseline
measurements. There was no change in respiratory rate
between groups (data not shown). These results demon-
strate that treatment with anti-C1q antibody prevent the
development of a respiratory function deficit.
We next compared the pathological impact of anti-C1q
antibody treatment. The diaphragms from all mice were
dissected 6 h post-NHS treatment and nerve terminals
assessed for complement deposition and neurofilament
immunoreactivity, the presence of the latter signifying
axonal integrity. Illustrative examples of this staining is
presented in Fig 2b. Fluorescently-labelled α-BTx (ma-
genta) labels the post-synaptic nicotinic ACh receptors
and visualises nerve terminals. Additionally, these mice
endogenously express CFP in the axons (blue). Early stage
complement product C3c (green) and end stage C5b-9b
MAC (orange) proteins were identified with immuno-
staining; staining was present overlying the terminals in
mice treated with isotype control mAb, and deposition
was prevented in mice treated with anti-C1q antibody
(Fig 2b). In mice treated with anti-C1q antibody, where
the neuronal fibre remains intact, neurofilament immuno-
staining (green) shows the axon entry and branching
pattern into the neuromuscular endplate, while anti-
GQ1b/GD3 IgM antibody (orange) follows the axonal
and perisynaptic Schwann cell membrane. The CFP la-
belling and neurofilament labelling are absent over the
α-BTx labelled terminal in mice treated with isotype
control mAb, while the anti-GQ1b/GD3 IgM antibody
remains. Mice from both treatment groups had similar
levels of anti-GQ1b/GD3 IgM antibody in the serum
(Table 1) and antibody visualisation at the nerve ter-
minal (Fig 2b, data not shown).
Mice treated with anti-GQ1b/GD3 IgM antibody plus
NHS and isotype control mAb, had significantly greater
intensity of C3 activation product C3c staining (p < 0.05)
and terminal complement components C5b-9 that form
the MAC pore (p < 0.05) (Fig 2c). The group treated with
anti-C1q antibody, showed virtually no staining for C3c
or C5b-9 complement components at the nerve termi-
nals, while showing robust neurofilament immunostain-
ing at the nerve terminal. In comparison, there was a
significant loss in axonal integrity in the isotype control
mAb treated mice (p < 0.05). These results demonstrate
that anti-C1q mAb can prevent neuropathological injury
in the mouse model of MFS. While these results are
consistent with our previous findings with anti-C5 anti-
body treatment, the lack of C3 activation as evidenced
by a reduction in C3c staining with anti-C1q antibody
treatment, demonstrates that the anti-C1q antibody
blocks classical complement activation upstream of C3
recruitment and/or cleavage, and thus may potentially
also reduce immune cell recruitment and consequently
exacerbated axonal pathology.
Treatment with C1q neutralising antibody protects
against neuropathy in a mouse model of AMAN
Similar to the MFS injury paradigm, a previously unre-
ported mouse model of AMAN was developed by per-
forming i.p. injections of anti-GM1 IgG antibody into
GalNAcT−/−-Tg(neuronal) mice to exclusively target axonal
membrane. Mice treated with anti-GM1 IgG antibody,
NHS and control mAb, developed a ‘wasp-like’ ab-
dominal phenotype with clearly visible difficulty in
breathing during the 6 h prior to termination of the
experiment. Baseline respiratory measurements from
whole-body plethysmography recordings showed no sig-
nificant differences between treatment groups for tidal
volume (anti-C1q antibody = 0.16 ± 0.02 ml, n = 5; control
mAb = 0.19 ± 0.02 ml, n = 5) or respiratory rate (anti-C1q
antibody = 277.6 ± 35 breaths/min, n = 5; control mAb =
318.3 ± 30.8 breaths/min, n = 5). At 16 h following anti-
GM1 antibody delivery, 50 mg/kg anti-C1q neutralising
antibody or control monoclonal antibody was administered
intravenously, followed by i.p. injection of NHS 30 min
later. Respiratory function was then monitored by whole-
body plethysmography at 6 h post-NHS. There was a
significant reduction in both tidal volume (19.1 ± 13.25 %,
n = 5) and respiratory rate (45.7 ± 15.87 %, n = 5) com-
pared to baseline in isotype control antibody treated mice
(Fig 3a). In comparison, mice treated with anti-C1q anti-
body had significantly greater tidal volume (80.44 ± 7.3 %,
n = 5, p < 0.01) and respiratory rate (119.5 ± 17.2 %, n = 5,
p < 0.05) compared to isotype control antibody treated
mice; these values did not significantly differ from base-
line. Representative respiratory traces are shown highlight-
ing the changes in breathing rate at baseline and 6 h after
treatment with anti-C1q antibody or isotype control anti-
body (Fig 3a).
Behavioural analysis was performed to test for any im-
pairment in motor activity of the mice. Mice treated
with isotype control mAb endured significantly less time
on the accelerating rotarod compared with anti-C1q
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antibody treated mice (anti-C1q antibody = 94 ± 6 s vs.
control mAb = 38.75 ± 5.2 s; p < 0.001, Fig 3b), but grip
strength did not change between groups. Poor perform-
ance on the rotarod is attributed to impaired respiratory
reserve as recorded using whole-body plethysmography,
rather than impairment of grip strength in the limbs
which did not change. This conclusion is corroborated
by the identification of anti-GM1 antibody binding over-
lying nerve terminals of the soleus leg muscle from all
mice in the absence of complement activation products,
indicating undetectable complement mediated injury to
leg nerve terminals (data not shown). Within the time-
frame of our experiment, the complement components
in NHS needed to drive complement activation/MAC
formation directly injure the diaphragm but do not be-
come sufficiently activated in the leg muscles to contrib-
ute to a motor functional deficit.
We assessed complement deposition and neurofilament
immunoreactivity in nerve terminals in the diaphragm from
all mice 6 h post-NHS treatment (Fig 3c), as described
above. Mice from both treatment groups had comparable
anti-GM1 IgG antibody serum concentration (Table 1) and
deposits at the nerve terminals (Fig 3c, data not shown).
GalNAcT−/−-Tg(neuronal) mice treated with anti-GM1 IgG
antibody plus NHS and control mAb, showed significant
staining for the early complement product C3c (p < 0.05)
and terminal complement components C5b-9 (p < 0.05)
compared to mice treated with anti-C1q antibody, where
deposits were undetectable (Fig 3c). In this model, neurofil-
ament immunostaining overlying the terminal was not
absent as was often the case in our MFS model, but instead
appeared fragmented compared to the normal distinct ter-
minal branching pattern. As such, the quantitative results
showed no change in axonal integrity between treatment
groups. Instead, we performed qualitative analysis and
observed the number of terminals with normal versus ab-
normal fragmented neurofilament immunostaining as a
measure of axonal integrity. Indeed, axonal integrity was
preserved at the nerve terminals of mice treated with anti-
C1q antibody compared to the disrupted neurofilament
staining in isotype control antibody treated mice (p < 0.01).
MAC signal was also less pronounced in this model than in
the MFS paradigm and could underlie the less severe neu-
rofilament disruption due to a more incomplete lesion at
this time-point. Together, these behavioural and immuno-
histological data indicate that neuropathy is evident in this
mouse model of AMAN and can be rescued by blockade
with an anti-C1q antibody.
Immune cell infiltration is impaired by C1q inhibition in a
model of GBS
Complement pathway products can recruit immune cells
and indeed immune cell infiltration has been observed
in GBS patient nerve pathology. To investigate immune
cell infiltration in an acute model of GBS and any modu-
lation by C1q neutralisation, diaphragm sections from
each model were examined for infiltrating cells around
the nerve terminals using several markers associated
with early and late stage inflammatory cells. In the MFS
model, the general leukocyte marker, CD11b, labelled
significantly more cells surrounding the nerve terminal
in mice treated with isotype control mAb than anti-C1q
antibody (Fig 4a, p < 0.05). There was a trend toward a
significant reduction in neutrophil cell number in anti-
C1q antibody treated tissue, but this did not reach sig-
nificance (Fig 4b). The number of CD11b positive cells
(Fig 4c) or neutrophils (Fig 4d) was not significantly dif-
ferent between treatment groups in the AMAN model.
Comparatively, the number of cells was lower in the
AMAN model compared to the MFS model. Macro-
phages were not observed in either model or treatment
groups, as would be expected over this short duration
time course (data not shown). These results demonstrate
early signs of leukocyte and neutrophil infiltration in
both mouse models of GBS, with a trend for a reduction
following treatment with anti-C1q antibody in the MFS
model of GBS.
Discussion and conclusions
This study presents two major developments in the field
of GBS modelling and immunotherapy. Firstly, we report
the establishment of a pure, readily reproducible and
(See figure on previous page.)
Fig. 2 C1q neutralisation attenuates injury in a mouse MFS model. a A significant reduction in tidal volume is shown in mice treated with isotype
control mAb (n = 3) compared to M1 (n = 4) antibody (p < 0.05). Representative flow-charts from the plethysmography recordings are shown for
each treatment group at 6 h post-NHS treatment. Bars represent mean ± SEM. b Top panels: Illustrative images show MAC (orange) and C3c
(green) deposited at nerve terminals (identified by α-BTx, red; CFP-positive axons, blue) from mice treated with control mAb, while this staining is
absent from those treated with anti-C1q antibody. Lower panels: Anti-ganglioside antibody (orange) is present at terminals from both treatment
groups, but neurofilament immunostaining (green) is only present at those terminals from mice treated with anti-C1q antibody. c The early and
end-stage complement products C3c and MAC, respectively, showed significantly greater deposits at control mAb treated mice (p < 0.05, p < 0.05,
respectively) than anti-C1q antibody treated mice (n = 3 control mAb, n = 4 anti-C1q antibody) nerve terminals. Axonal integrity was a measure of
neurofilament immunostaining overlying the endplate. Axonal integrity was significantly more intact at anti-C1q antibody protected mice nerve
terminals compared to the control mAb group (p < 0.05). Box and whisker plots represent the spread of all data points per condition and significance
was based on Mann–Whitney statistical analysis of the median from each animal per treatment. * p < 0.05, unpaired student t-test (a), Mann–Whitney
test (b). Scale bar = 20 μm. AGAb = anti-ganglioside antibody, nAChR = nicotinic acetylcholine receptor
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temporally precise model of AMAN in mice. Using newly
developed transgenic mice that selectively express com-
plex gangliosides only in their axonal membranes [41], we
are able to exclusively target axons in vivo with anti-GM1
ganglioside antibody and a source of complement, result-
ing in the axonopathic phenotype described herein. The
importance of creating an AMAN model lies in under-
standing the mechanisms underlying the distinct features
of axonal and demyelinating GBS variants, and tailoring
therapeutic approaches accordingly. Secondly, we report
the successful attenuation of clinical and pathological dis-
ease in the acute AMAN and MFS models of GBS by tar-
geting the initiating protein of the complement cascade,
C1q. This is an as yet untargeted stage of the complement
pathway in GBS models and may have advantages over
terminal component complement inhibitors. Improved
and specific pathway-targeted therapies are greatly needed
in GBS, where no new treatments have been approved
since the introduction of intravenous immunoglobulin
and plasma exchange over 20 years ago.
GM1 antibodies are strongly associated with the axonal
variant of GBS, AMAN [17, 25]. It is unclear why motor
axons are specifically targeted in AMAN as GM1 is also
present in myelin, and in sensory axons [24]. The bound-
ary of this dichotomisation is the subject of considerable
on-going clinical interest [38]. By developing a mouse in
which complex gangliosides are exclusively expressed in
neurons, it is possible to target this site and study the
mechanisms that purely reflect axonal injury. Conversely,
we are similarly able to study mice in which GM1 expres-
sion is restricted to Schwann cell membranes [41]. Here,
we report that GM1 ganglioside was successfully reconsti-
tuted in brain extracts from GalNAcT−/−-Tg(neuronal)
mice compared to GalNAcT−/− mice. Further, we proved
by topical immunostaining of the triangularis sterni
nerve-muscle preparations that GM1 was only detectable
on axonal membranes, which is critical to developing a
pure AMAN model. This represents an important step
towards evaluating novel therapeutics in AMAN com-
pared to using wild type mice for several reasons. By ex-
pressing GM1 in neurons, we can be certain that the early
pathology we observe is solely due to direct axonal injury.
As GM1 is present on the kranocyte, a parajunctional
fibroblast that caps the motor nerve terminal in rodents
[4] and in Schwann cell membranes, binding and injury to
these sites may confound rigorous interpretation of data,
in comparison with wild type mice. An additional major
limitation to modelling AMAN in wild type mice is the
extensive sequestration of anti-ganglioside antibodies by
other extra-neural plasma membranes that limits the
bioavailability of the antibodies for targeting axonal mem-
branes (Cunningham et al., Brain in press). This seques-
tration of antibody by extra-neural cells may in part
account for the poor axonal staining visualised with the
DG2 anti-GM1 antibodiesin wild-type mice.
In our previously reported acute mouse model of the
MFS variant of GBS, administration of anti-GQ1b/GD3
ganglioside antibody and a source of complement caused
a respiratory paralytic phenotype in wild type mice [15].
Whilst we have never previously been able to reproducibly
induce a similar phenotype with anti-GM1 antibody in
wild type mice (preferring instead to use anti-GD1a anti-
body in GD3 synthase−/− mice that overexpress GD1a
[22]), we have here recapitulated this injury paradigm
using GalNAcT−/−-Tg(neuronal) mice receiving an injec-
tion of anti-GM1 ganglioside antibody to produce an
entirely original AMAN model. The clinical and mor-
phological phenotypes were successfully reproduced in
this model: mice developed weakness, respiratory dys-
function and associated complement deposition and
pathology in diaphragm nerve terminals. The new op-
portunities provided by this novel model are profound
- it is now possible to directly and specifically target
the axolemma at nerve terminals and the nodes of
Ranvier, study associated nodal pathology, and deter-
mine the downstream consequences on function and
(See figure on previous page.)
Fig. 3 C1q neutralisation attenuates injury in a novel mouse model of AMAN. a Tidal volume and respiratory rate decreased compared to baseline
measurements in both treatment groups. Tidal volume and respiratory rate reached a significant reduction in mice treated with isotype control mAb
(p < 0.01, p < 0.05, respectively) compared to anti-C1q antibody (n = 5/group). Representative flow-charts from the plethysmography recordings are
shown for each treatment group at baseline and 6 h post-NHS treatment. b Behavioural tests showed isotype control mAb treated mice (n = 5) spent
significantly less time on the accelerating rotarod than did mice treated with anti-C1q antibody (p < 0.001). There was no significant difference in grip
strength between groups. c Top panels: Illustrative images show MAC (orange) and C3c (green) deposited at nerve terminals (nAChR’s identified
by α-BTx, red; CFP-positive axons, blue) from mice treated with control mAb, while this staining is absent from those treated with anti-C1q
antibody. Lower panels: Anti-ganglioside antibody (orange) is present at terminals from both treatment groups, but neurofilament immunostaining (green)
is only present at those terminals from mice treated with anti-C1q antibody. d The diaphragm nerve terminals were identified by fluorescently
labelled α-BTx. Nerve terminals were immunohistochemically assessed for complement deposits and axonal integrity. The early and end-stage
complement products C3c and MAC, respectively, showed significantly greater deposits at control mAb treated mice than anti-C1q antibody
treated mice nerve terminals (p < 0.01). Axonal integrity was a measure of percentage “normal” neurofilament immunostaining overlying the
endplate. Axonal integrity was significantly more intact at anti-C1q antibody protected mice nerve terminals compared to the isotype control
mAb group. Box and whisker plots represent the spread of all data points and significance was based on Mann–Whitney statistical analysis of
the median from each animal per treatment. * p < 0.05; ** p < 0.01; *** p < 0.001, unpaired student t-test (a,b), Mann–Whitney test (c). Scale
bar = 20 μm. AGAb = anti-ganglioside antibody, nAChR = nicotinic acetylcholine receptor
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axon fate, currently a major area in GBS clinical research
[38]. This model can now be adapted and extended over
time to allow the development of the GBS pathological
features and motor deficits that are observed in patients,
subsequently allowing the effective stages of therapeutic
intervention to be scrutinised.
Fig. 4 Immune cell infiltration in acute MFS and AMAN models. a In the MFS model of disease, there was significantly less CD11b positive cells
per field of view (FOV) within the proximity of the NMJ in animals who were treated with anti-C1q antibody. b No significance in NIMP-R positive
cells existed between the two groups, despite a trend towards lower numbers in the anti-C1q antibody treated group. c In the AMAN model of
disease, there was no significant difference between anti-C1q antibody treated and control mAb-treated animals in either CD11b or (d) NIMP-R14
positive cells. Neutrophils appeared to be absent within the proximity of the NMJ in this model. Bars represent mean ± SEM, *p < 0.05, unpaired
student t-test. Scale bars = 20 μm. nAChR = nicotinic acetylcholine receptor
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Complement activation on axolemmal membranes has
been associated with AMAN in human autopsy studies
and animal modelling [8, 9, 22, 36] and thus presents a
promising target for therapy. Halstead et al. (2008), estab-
lished an MFS mouse model and used it to show that in-
hibition of the terminal MAC pore formation using an
anti-C5 monoclonal antibody could abrogate pathophysi-
ology [15]. A similar model, focussed on nodal pathology,
was also investigated by us with a similarly protective out-
come [22]. Using the current in vivo AMAN model with
anti-GM1 antibody we here report that blockade of the
classical complement pathway at the initiating stage using
the anti-C1q monoclonal antibody M1 [28] similarly at-
tenuates dysfunction and pathology. Anti-C1q antibody
directly targets C1q to inhibit classical complement path-
way activation and to prevent MAC pore formation and
calcium influx, the latter step being the target of anti-C5
antibody. C1q neutralisation may be beneficial over C5
inhibition in terms of infectious risk, as the mannose-
binding lectin pathway is still functional and the host
should therefore retain a defence system against bacterial
infections. Additionally, blocking C1q will eliminate the
generation of anaphylotoxins C3a and C5a, which cause
effector cell chemotaxis, binding and degranulation, with
the potential for further downstream injury [42]. The
safety of blocking C1q in human studies with a therapeutic
antibody has yet to be determined. In this hyper-acute
model, we provide the evidence that anti-C1q antibody
can attenuate complement-mediated injury by applying
the anti-C1q antibody prior to addition of an active com-
plement source to the mouse. In future studies in which
the model is prolonged, studying the efficacy of C1q
neutralization after disease onset will be of interest as this
better represents human clinical situations.
Our acute GBS disease models are complement-
mediated and we know that dysfunction correlates with
MAC pore formation [12, 14, 15]. However other steps
within the complement cascade could play a role in injury.
Here we studied effector cell recruitment at the diaphragm
nerve terminals and any effect of early complement com-
ponent blockade. Complement activation has the capacity
to recruit immune cells to injured peripheral nerves [31],
and it is known that neutrophils and macrophages can in-
filtrate the injured nerve within two days of injury [11].
We report an increase in CD11b positive cells and neutro-
phils in our MFS model, which was attenuated by anti-
C1q antibody treatment. This finding demonstrates that
blocking C1q can successfully reduce immune cell infiltra-
tion. There was no change in immune cell number in our
AMAN mouse model, suggesting immune cells are not
involved in the pathogenesis reported over this short time
scale as modelled in this paradigm. Lack of immune cell
invasion may be attributed to the lower overall level of
complement activation observed and production of
subsequent soluble signals. The acute duration of the para-
digm may also limit immune cell recruitment into the ter-
minals or nodes of Ranvier; it will be of interest to assess
their role in extended models in the future. Macrophage
infiltration into the periaxonal space of nerves and sur-
rounding degenerating axons has been observed in aut-
opsy tissue from AMAN patients [8, 9]. A rabbit model of
AMAN suggested this recruitment of macrophages into
the nerve begins at the acute progressive phase (~2 days)
of disease but did not yet correspond with sites of comple-
ment deposition [36]. Instead macrophage invasion was
significantly more frequent at the early recovery phase
(~2 weeks), suggesting that these cells are involved in
clearance of degenerating fibres rather than injury. At
such an acute time-point in our models we did not ob-
serve any macrophage infiltration. Further study in an ex-
tended model will be necessary to determine which
immune cells invade the site and their impact on injury
and recovery. Extending the model to several days will
also be informative for testing the long-term prognosis
and suitability of different therapeutic targets. For example
it is known that C1q plays a role in neurite outgrowth and
regeneration [26]; therefore timing of therapy may be
crucial.
Using Fcγ receptor expressing NK cells, it has been
shown that anti-C1q antibody does not attenuate antibody-
dependent cytotoxicity [28]. This suggests that any attenu-
ation of injury reported here and in the NMO spinal cord
demyelinating injury model most likely has been through
mediation of the complement pathway [28]. Our model
currently concentrates on one aspect of AMAN pathogen-
esis and its inhibition; namely anti-ganglioside antibody
activation of the classical complement pathway and
subsequent complement-dependent nerve injury and its
attenuation by anti-C1q antibody, respectively. However,
anti-ganglioside antibody can conceivably cause injury
through complement-independent mechanisms. Indeed, it
has recently been reported that nodal and axonal injury
can be mediated through anti-ganglioside antibody im-
mune complex formation and recruitment of macrophages
through their Fcγ receptors in a mouse model [16]. It is
likely that more than one mechanism will be active simul-
taneously in human GBS, and it is therefore important to
broadly consider inflammatory pathways whilst imple-
menting therapies.
The original characterisation of anti-C1q monoclonal
antibody demonstrated an apparent binding affinity of
11 pM, which is comparable to other approved mono-
clonal antibody therapeutics including rituximab to its
antigen CD20 (~8nM) [28, 33]. The results provided
here suggest that C1q is a valid target for GBS, and the
next step will be the generation of a humanized, non-
immunogenic antibody with suitable pharmacokinetics
in humans.
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